Noxopharm Limited Stock Net Income
| NOXOFDelisted Stock | USD 0.04 0.00 0.00% |
Fundamental analysis of Noxopharm allows traders to better anticipate movements in Noxopharm's stock price by examining its financial health and performance throughout various phases of its business cycle.
Noxopharm |
Noxopharm Limited Company Net Income Analysis
Noxopharm's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Noxopharm Net Income | (18.67 M) |
Most of Noxopharm's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Noxopharm Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Noxopharm Limited reported net income of (18.67 Million). This is 105.47% lower than that of the Healthcare sector and 126.65% lower than that of the Biotechnology industry. The net income for all United States stocks is 103.27% higher than that of the company.
Noxopharm Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Noxopharm's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Noxopharm could also be used in its relative valuation, which is a method of valuing Noxopharm by comparing valuation metrics of similar companies.Noxopharm is currently under evaluation in net income category among its peers.
Noxopharm Fundamentals
| Return On Equity | -0.58 | |||
| Return On Asset | -0.16 | |||
| Operating Margin | (1.80) % | |||
| Current Valuation | 22.3 M | |||
| Shares Outstanding | 292.24 M | |||
| Shares Owned By Insiders | 33.53 % | |||
| Shares Owned By Institutions | 1.00 % | |||
| Price To Book | 2.36 X | |||
| Price To Sales | 7.11 X | |||
| Revenue | 5.43 M | |||
| Gross Profit | (2.35 M) | |||
| EBITDA | (18.33 M) | |||
| Net Income | (18.67 M) | |||
| Cash And Equivalents | 14.01 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 160.62 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 9.13 X | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (13.73 M) | |||
| Earnings Per Share | (0.03) X | |||
| Beta | 1.25 | |||
| Market Capitalization | 38.58 M | |||
| Total Asset | 26.59 M | |||
| Net Asset | 26.59 M |
About Noxopharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Noxopharm Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Noxopharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Noxopharm Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Noxopharm Pink Sheet
If you are still planning to invest in Noxopharm Limited check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Noxopharm's history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |